Venlafaxine Prodrug Polymorphs for Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The metabolite of venlafaxine, which is a reuptake inhibitor of 5-hydroxytryptamine (5-HT) and norepinephrine (NA), has increased hydrophilicity due to more hydroxyl groups, leading to decreased absorption rates via oral or transdermal routes and potential pre-system side effects, necessitating the development of derivatives that overcome these limitations.
Innovation Solution
The synthesis of polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, specifically crystal forms I, II, III, IV, and V, which exhibit improved stability and bioavailability through specific X-ray diffraction patterns and melting points, allowing for enhanced therapeutic effects and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the metabolite (III) with increased hydroxyl groups is used to enhance therapeutic effects, then the therapeutic efficacy is improved, but the absorption rate decreases due to increased hydrophilicity
Solution Approach 1:
The patent modifies the chemical structure by introducing a prodrug group (4-methylbenzoate ester) to change the physical and chemical parameters of the molecule. This structural modification reduces hydrophilicity and increases lipid solubility, thereby improving absorption rate while maintaining the ability to release the active metabolite (III) in vivo
Solution Approach 2:
The patent introduces an intermediate compound (prodrug) that serves as a carrier for the active metabolite (III). This prodrug intermediate facilitates absorption through biological membranes and then releases the active metabolite in vivo, acting as a mediator between the administered form and the active therapeutic form
2Reliability
If the metabolite (III) is used directly to treat central nervous system diseases, then the therapeutic effects are enhanced, but pre-system side effects increase due to decreased absorption
Solution Approach 1:
By modifying the chemical parameters of the metabolite (III) through prodrug design, the patent changes its absorption characteristics. The modified compound shows improved lipid solubility and absorption rate, reducing the proportion of unabsorbed drug that causes pre-system side effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent converts the harmful effect of high hydrophilicity (which causes poor absorption and pre-system side effects) into a beneficial feature by designing a prodrug with balanced properties. The prodrug structure allows controlled release of the active metabolite, turning the potential harm of high reactivity into a controlled therapeutic advantage
3Reliability
If multiple polymorphs are synthesized to improve stability and bioavailability, then the therapeutic performance is enhanced, but the manufacturing complexity increases
Solution Approach 1:
The patent identifies and characterizes specific local crystal structure qualities (polymorphs with distinct XRD patterns and melting points) that provide superior stability and bioavailability. By focusing on specific polymorphic forms with defined characteristics rather than general crystalline structures, the patent enables targeted manufacturing with controlled quality attributes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystal forms demonstrate higher and more stable melting points, improved bioavailability, and reduced side effects, making them suitable for treating central nervous system diseases associated with 5-HT and NA reuptake, such as depression and anxiety disorders.
Implementation Method 1
characterized in that the crystal form I exhibits a powder X-ray diffraction pattern obtained using CuKα radiation and having characteristic peaks
Implementation Method 2
exhibits a powder X-ray diffraction pattern having characteristic peaks expressed in degrees 2θ (±0.2° 2θ)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.